We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-20.62%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.84B
AUM Growth
-$1.19B
Cap. Flow
+$214M
Cap. Flow %
5.56%
Top 10 Hldgs %
54.93%
Holding
140
New
25
Increased
22
Reduced
18
Closed
27

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$59.7M
3
ZYME icon
Zymeworks
ZYME
+$47.4M
4
NVRO
NEVRO CORP.
NVRO
+$39.5M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$33.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$152M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$78.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$53.8M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$37.3M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 0.28%
3 Technology 0.27%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$2.04B
$349M 9.1%
11,670,057
+2,253,855
+24% +$59.7M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$310M 8.07%
6,065,726
+200,000
+3% +$13.4M
NBIX icon
3
Neurocrine Biosciences
NBIX
$18.2B
$265M 6.91%
3,063,263
-549,291
-15% -$53.8M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$255M 6.65%
3,319,450
+116,044
+4% +$10.4M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$233M 6.06%
25,182,364
+50,000
+0.2% +$475K
BBIO icon
6
BridgeBio Pharma
BBIO
$16.4B
$194M 5.07%
6,706,268
– –
KOD icon
7
Kodiak Sciences
KOD
$2.5B
$175M 4.55%
3,663,557
– –
ZYME icon
8
Zymeworks
ZYME
$1.62B
$126M 3.28%
3,560,999
+1,157,973
+48% +$47.4M
NVRO
9
DELISTED
NEVRO CORP.
NVRO
$107M 2.8%
1,092,068
+328,182
+43% +$39.5M
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$94.1M 2.45%
3,484,358
+146,836
+4% +$4.79M
ATNX
11
DELISTED
Athenex, Inc. Common Stock
ATNX
$89.3M 2.32%
576,623
– –
MGTX icon
12
MeiraGTx Holdings
MGTX
$1.08B
$86.5M 2.25%
6,433,277
– –
ZGNX
13
DELISTED
Zogenix, Inc.
ZGNX
$85.4M 2.22%
3,452,921
-256,231
-7% -$9.33M
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$65.8M 1.71%
15,711,334
+1,075,000
+7% +$4.63M
MYOK
15
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$61.6M 1.6%
1,314,209
+107,798
+9% +$6.91M
KRRO icon
16
Korro Bio
KRRO
$145M
$54M 1.41%
60,686
– –
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
$52.5M 1.37%
332,226
– –
ADMA icon
18
ADMA Biologics
ADMA
$2.02B
$47.8M 1.24%
16,584,802
+5,063,700
+44% +$17.5M
VBIV
19
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$43.7M 1.14%
1,531,719
– –
TVTX icon
20
Travere Therapeutics
TVTX
$5.17B
$42.2M 1.1%
2,890,608
– –
BPMC
21
DELISTED
Blueprint Medicines
BPMC
$40.3M 1.05%
688,624
+70,000
+11% +$4.5M
REGN icon
22
Regeneron Pharmaceuticals
REGN
$72.9B
$39.1M 1.02%
+80,000
New +$33M
CRNX icon
23
Crinetics Pharmaceuticals
CRNX
$8.88B
$38M 0.99%
2,587,953
– –
VRCA icon
24
Verrica Pharmaceuticals
VRCA
$89M
$37.3M 0.97%
341,041
– –
EIDX
25
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$33.7M 0.88%
686,922
-10,602
-2% -$540K
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Perceptive Advisors held 140 positions worth $3.84B, down 24% from $5.03B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors deployed $214M of net new capital in Q1 2020, opening 25 new positions and adding to 22 existing holdings. Its largest new stake was Gilead Sciences: 1,500,000 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $78.1M trimmed.

  • Perceptive Advisors's largest Q1 2020 buy was Gilead Sciences: 1,500,000 shares worth $11.2M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2020, an estimated $59.7M increase.
  • Perceptive Advisors's biggest Q1 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $78.1M.
  • Perceptive Advisors fully exited Amarin Corp in Q1 2020, selling an estimated $152M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $3.84B portfolio in Q1 2020.
  • Perceptive Advisors opened 25 new positions and closed 27 in Q1 2020.
  • Perceptive Advisors's portfolio value fell 24% quarter-over-quarter to $3.84B.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.